Recent market reports forecast significant growth in the progressive pulmonary fibrosis market, set to reach $2.7 billion by 2035, and the global asthma and COPD drugs market, projected to hit US$ 82.2 billion by 2036. The Asia Pacific pharma 4.0 market is also expanding rapidly, driven by digital technologies like AI and IoT.
Deupirfenidone, a deuterated form of pirfenidone, is set to be tested in a phase 3 trial this year after successful phase 2b results. The FDA and European Commission have granted orphan drug designation to support its late-stage development.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07540988 |
FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression |
NOT_YET_RECRUITING | PHASE3 |
| NCT07366034 |
A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With Interstitial Lung Disease (FIBRONEER-chILD) |
RECRUITING | PHASE3 |
| NCT07201922 |
A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis |
RECRUITING | PHASE3 |
| NCT06806592 |
A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseases |
RECRUITING | PHASE3 |
| NCT06238622 |
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast |
RECRUITING | PHASE3 |
